Di-2,4-dichlorobenzyltin-2-(2-(thiophen-2-formyl)hydrazono)-propanoic carboxylate complex I{[C_(4)H_(3)S(O)C=N-N=C(CH_(3))COO]_(2)[(2,4-Cl_(2)-C_(6)H_(3)CH_(2))_(2)Sn]_(2)(CH_(3)OH)_(2)}and di-2,4-dichlorobenzyltin-2-...Di-2,4-dichlorobenzyltin-2-(2-(thiophen-2-formyl)hydrazono)-propanoic carboxylate complex I{[C_(4)H_(3)S(O)C=N-N=C(CH_(3))COO]_(2)[(2,4-Cl_(2)-C_(6)H_(3)CH_(2))_(2)Sn]_(2)(CH_(3)OH)_(2)}and di-2,4-dichlorobenzyltin-2-(2-(thio-phen-2-formyl)hydrazono)-3-phenylpropanoic carboxylate complexⅡ{[C_(4)H_(3)S(O)C=N-N=C(PhCH_(2))COO](2,4-Cl_(2)-C_(6)H_(3)CH_(2))_(2)Sn}n were synthesized and characterized by IR,^(1)H,^(13)C and^(119)Sn NMR spectra,HRMS,elemental analysis and thermal stability analysis,and the crystal structures were determined by X-ray diffraction.The crystal of complex I belongs to monoclinic system,space group P2_(1/n)with a=11.987(3),b=35.359(9),c=12.982(3)Å,β=103.028(5)°,Z=4,V=5361(2)Å3,Dc=1.688 Mg·m^(–3),μ(MoKα)=1.463 mm^(–1),F(000)=2704,R=0.0572 and wR=0.1423.The crystal of complexⅡis of monoclinic system,space group P2_(1/n)with a=15.5758(17),b=9.6020(10),c=19.599(2)Å,β=98.886(2)°,Z=4,V=2896.0(5)Å3,Dc=1.663 Mg·m^(–3),μ(MoKα)=1.357 mm^(–1),F(000)=1440,R=0.0341 and wR=0.0936.In vitro antitumor activities of both complexes were evaluated by MTT against three human cancer cell lines(MCF7,NCI-H460 and HepG2),and they all exhibited good antitumor activity.The interaction between complexes and calf thymus DNA was studied by UV-vis and fluorescence spectroscopy,it indicated intercalation as probable mode of interaction.展开更多
基金the Natural Science Foundation of Hunan Province(No.2020JJ8096)。
文摘Di-2,4-dichlorobenzyltin-2-(2-(thiophen-2-formyl)hydrazono)-propanoic carboxylate complex I{[C_(4)H_(3)S(O)C=N-N=C(CH_(3))COO]_(2)[(2,4-Cl_(2)-C_(6)H_(3)CH_(2))_(2)Sn]_(2)(CH_(3)OH)_(2)}and di-2,4-dichlorobenzyltin-2-(2-(thio-phen-2-formyl)hydrazono)-3-phenylpropanoic carboxylate complexⅡ{[C_(4)H_(3)S(O)C=N-N=C(PhCH_(2))COO](2,4-Cl_(2)-C_(6)H_(3)CH_(2))_(2)Sn}n were synthesized and characterized by IR,^(1)H,^(13)C and^(119)Sn NMR spectra,HRMS,elemental analysis and thermal stability analysis,and the crystal structures were determined by X-ray diffraction.The crystal of complex I belongs to monoclinic system,space group P2_(1/n)with a=11.987(3),b=35.359(9),c=12.982(3)Å,β=103.028(5)°,Z=4,V=5361(2)Å3,Dc=1.688 Mg·m^(–3),μ(MoKα)=1.463 mm^(–1),F(000)=2704,R=0.0572 and wR=0.1423.The crystal of complexⅡis of monoclinic system,space group P2_(1/n)with a=15.5758(17),b=9.6020(10),c=19.599(2)Å,β=98.886(2)°,Z=4,V=2896.0(5)Å3,Dc=1.663 Mg·m^(–3),μ(MoKα)=1.357 mm^(–1),F(000)=1440,R=0.0341 and wR=0.0936.In vitro antitumor activities of both complexes were evaluated by MTT against three human cancer cell lines(MCF7,NCI-H460 and HepG2),and they all exhibited good antitumor activity.The interaction between complexes and calf thymus DNA was studied by UV-vis and fluorescence spectroscopy,it indicated intercalation as probable mode of interaction.